L ung cancer is the leading cause of cancer-related deaths in the United States (World Health Organization, 2018) . Although the lung cancer mortality rate has dramatically decreased during the past two decades-primarily because of the decrease of cigarette smoking-the incidence rate of lung cancer still ranks second in both genders (American Cancer Society [ACS], 2019).
Patients with lung cancer have one of the lowest five-year survival rates (McCarthy, 2014) . When diagnosed at an early stage, patients with lung cancer have a 52% survival rate at five years, but the five-year survival rate drops to 15% when diagnosed at a late stage (McCarthy, 2014) . To diagnose lung cancer at an early stage and increase the five-year survival rate, obtaining lung cancer screening at an early stage is essential (Parker et al., 2015) .
In 1970, ACS recommended chest x-ray with or without sputum cytology to find lung cancer early (Wender et al., 2013) . However, in 1980, ACS retracted this guideline, because evidence was lacking to support chest x-ray's efficiency to decrease the lung cancer-related mortality rate (Wender et al., 2013) . In 2002, the National Lung Screening Trial (NLST) research team began to conduct an eightyear randomized clinical trial to test the efficiency of chest x-ray and low-dose computed tomography (LDCT) in decreasing the lung cancer mortality rate (Aberle et al., 2013) . This clinical trial was conducted among 53,454 participants who were at high risk for lung cancer (being aged 55-74 years, having a smoking history of at least 30 pack-years during the lifetime, being a current smoker or having quit smoking in the past 15 years) (Aberle et al., 2013) . Participants were required to receive three annual lung cancer screenings with chest x-ray or LDCT. Results showed that LDCT can significantly decrease the lung cancer mortality rate by 20%, compared to chest x-ray (Tota, Ramanakumar, & Franco, 2014; Wender et al., 2013 
